Dec 15, 2009
This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interview Dr. Stephen Salloway about his paper on using bapineuzumab in mild to moderate Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Heidenhain variant of Creutzfeldt Jakob disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on triptans. The participants had nothing to disclose except Drs. Burns & Salloway. Dr. Burns serves on the Neurology Podcast Committee.Dr. Salloway serves on scientific advisory boards for Myriad Genetics, Inc, Elan Corporation, Sanofi-aventis, Eisai Inc., and Pfizer; serves on the editorial board of the Journal of Neuropsychiatry and Clinical Neurosciences; receives royalties from American Psychiatric Press Inc and Humana Press; received speaker honoraria from Eisai Inc., Pfizer, Novartis, Forest Laboratories, Inc. and Elan Corporation; serves as a consultant to Merck Serono and Medivation-data safety committee; receives research support from Elan Corporation, Wyeth, Bristol-Myers Squibb, Alzheimers Disease Neuroimaging Initiative, Dominantly Inherited Alzheimers Network, Aging Brain: DTI, Subcortical Ischemia and Behavior and NIH [NIA 1 R03 AGO23916-01A1]; receives funding from The Norman and Rosalie Fain Family Foundation.